Company news

CG Oncology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 23, 2024

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

May 2, 2024

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

April 25, 2024

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

April 23, 2024

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

March 27, 2024

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

February 26, 2024

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 29, 2024

CG Oncology Announces Pricing of Upsized Initial Public Offering

January 23, 2024

← Newer news releases

Decks

The 5 newest of 30 decks. Every deck is listed under its year.